Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 2 | 2017
With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…
Methicillin-Resistant Staphyloccocus Aureus Infections (MRSA) | Outpatient Parenteral Antibiotic Therapy (OPAT) | Current Treatment | Physician Insights | US | 2017
Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…
Hospital-Treated Gram-Negative Infections | Current Treatment: Physician Insights | US | 2017
Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…